Skip to main content
Clinical Trials/NCT05322642
NCT05322642
Unknown
N/A

Efficacy of the Unified Protocol for Transdiagnostic Treatment for Adolescents With Symptoms of Anxiety and Depression: a School-based Randomized Controlled Trial

Eduardo Fonseca Pedrero1 site in 1 country300 target enrollmentDecember 1, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
Anxiety Disorder
Sponsor
Eduardo Fonseca Pedrero
Enrollment
300
Locations
1
Primary Endpoint
Anxiety symptoms
Last Updated
4 years ago

Overview

Brief Summary

The main goal is to assess the efficacy of the Unified Protocol for the Transdiagnostic Treatment (UP-A; Ehrenreich-May et al., 2018) for Adolescents with moderate emotional symptoms in educational settings The goal is to prevent emotional symptoms and improve the socio-emotional adjustment.

Detailed Description

Emotional problems, such as anxiety and depression, are among the leading causes of associated disability and burden of disease worldwide among young people. Therefore, it is necessary to address this emerging social challenge through the implementation of prevention strategies in relevant stages of development such as adolescence. In recent years, a transdiagnosis approach to emotional disorders has been promoted, highlighting the unified protocol for transdiagnostic treatment of emotional disorders and symptoms in its different versions (adulthood, adolescence, and childhood). In this context, the main goal is to assess the efficacy of the Unified Protocol for the Transdiagnostic Treatment (UP-A; Ehrenreich-May et al., 2018) for Adolescents with moderate emotional symptoms in educational settings The goal is to prevent emotional symptoms and improve the socio-emotional adjustment. Adolescents aged 12-18 at high risk of for anxiety and depression disorders (cut-off scores 10-15 points, PHQ-9 and GAD-7) are selected. The design is a randomized controlled trial with two groups: active control (relaxation) and experimental (UP-A). Pre-test, post-test, and follow-up at 6, 12 and 18 months will be carried out. The impact of different behavioural, cognitive, affective, social, and academic functioning indicators is analyzed, as well as their effects in the short, medium, and long term. The satisfaction of the program by users (students, parents, and professionals) will also be evaluated. The implementation and validation of manualized and empirically validated psychological intervention programs, such as UP-A, should be a priority in educational and socio-health policies.

Registry
clinicaltrials.gov
Start Date
December 1, 2021
End Date
January 30, 2024
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Eduardo Fonseca Pedrero
Responsible Party
Sponsor Investigator
Principal Investigator

Eduardo Fonseca Pedrero

Director

University of La Rioja

Eligibility Criteria

Inclusion Criteria

  • Be 12-18 years old
  • Written informed consent from adolescent and legal guardian
  • Being able to understand and read Spanish.
  • Moderate depressive and anxiety symptoms according to the screening (score moderate level in the PHQ-9 and GAD-7).

Exclusion Criteria

  • Being diagnosed a mental disorder or alcohol and/or substance dependence disorder.
  • The presence of high suicidal risk
  • A medical disease or condition which prevent the participant from carry out the psychological treatment.
  • Receiving another psychological treatment while the study is still ongoing.
  • The increase and/or changes in the medication of participants receiving pharmacological treatment during the study

Outcomes

Primary Outcomes

Anxiety symptoms

Time Frame: Baseline to 18 months after start of interventions

Change in the Generalised Anxiety Disorder Assessment (GAD-7) total score. GAD-7 total score for the seven items ranges from 0 to 21.Higher scores mean a worse outcome.

Depression symptoms

Time Frame: Baseline to 18 months after start of interventions

Change in the Patient Health Questionnaire-9 (PHQ-9) total score. PHQ-9 total score for the nine items ranges from 0 to 27.Higher scores mean a worse outcome.

Secondary Outcomes

  • Educational achievement outcome(Baseline to 18 months after start of interventions)
  • Transdiagnostic dimensions(Baseline to 18 months after start of interventions)
  • Health-related quality of life(Baseline to 18 months after start of interventions)
  • Positive and Negative Affect(Baseline to 18 months after start of interventions)
  • Emotional and behavioural problems(Baseline to 18 months after start of interventions)

Study Sites (1)

Loading locations...

Similar Trials